Sotera Health Company (SHC)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 12/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.39% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Here’s Why Sotera Health Company (SHC) Surges 25% in Q2
- Research Tools & Consumables Stocks Q2 Recap: Benchmarking Sotera Health Company (NASDAQ:SHC)
- Sotera Health Company (SHC): Buy, Sell, or Hold Post Q2 Earnings?
- Sotera Health (SHC) Q2 2026 Earnings Call Transcript
- Sotera Health Company (SHC) Reported Positive Results Amid Litigation Wins
- Sotera Health Q2 Earnings Call Highlights
- Sotera Health Company (SHC) Beats Q2 Earnings and Revenue Estimates
- Sotera Health Company (NASDAQ:SHC) Surprises With Strong Q2 CY2026
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Sotera Health Company.
Full SHC Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.